CA3139948A1 - Crystalline form of sofpironium bromide and preparation method thereof - Google Patents
Crystalline form of sofpironium bromide and preparation method thereof Download PDFInfo
- Publication number
- CA3139948A1 CA3139948A1 CA3139948A CA3139948A CA3139948A1 CA 3139948 A1 CA3139948 A1 CA 3139948A1 CA 3139948 A CA3139948 A CA 3139948A CA 3139948 A CA3139948 A CA 3139948A CA 3139948 A1 CA3139948 A1 CA 3139948A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- crystalline form
- content
- crystalline
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851880P | 2019-05-23 | 2019-05-23 | |
| US62/851,880 | 2019-05-23 | ||
| PCT/JP2020/020210 WO2020235665A1 (en) | 2019-05-23 | 2020-05-22 | Crystalline form of sofpironium bromide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3139948A1 true CA3139948A1 (en) | 2020-11-26 |
Family
ID=72146250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3139948A Pending CA3139948A1 (en) | 2019-05-23 | 2020-05-22 | Crystalline form of sofpironium bromide and preparation method thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220298108A1 (https=) |
| EP (1) | EP3972955A4 (https=) |
| JP (2) | JP6748329B1 (https=) |
| KR (1) | KR20220011671A (https=) |
| CN (1) | CN114008023B (https=) |
| AU (1) | AU2020277881B2 (https=) |
| BR (1) | BR112021023241A2 (https=) |
| CA (1) | CA3139948A1 (https=) |
| CL (1) | CL2021003047A1 (https=) |
| CO (1) | CO2021017456A2 (https=) |
| IL (1) | IL288285B1 (https=) |
| MX (1) | MX2021014163A (https=) |
| MY (1) | MY206154A (https=) |
| PH (1) | PH12021552915A1 (https=) |
| SG (1) | SG11202111678WA (https=) |
| TW (2) | TWI838531B (https=) |
| WO (1) | WO2020235665A1 (https=) |
| ZA (1) | ZA202109514B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220298108A1 (en) * | 2019-05-23 | 2022-09-22 | Kaken Pharmaceutical Co., Ltd. | Crystalline form of sofpironium bromide and preparation method thereof |
| EP4213158A1 (en) | 2020-11-13 | 2023-07-19 | Ahead Biocomputing, Co. Ltd | Information processing device, information processing method, recording medium recording information processing program, and information processing system |
| CN115925603B (zh) * | 2022-11-29 | 2025-07-22 | 山东齐都药业有限公司 | 索吡溴铵的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7417147B2 (en) * | 2005-11-10 | 2008-08-26 | Bodor Nicholas S | Soft anticholinergic zwitterions |
| ATE529399T1 (de) * | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Sanfte anticholinerge ester |
| MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
| US9512166B2 (en) * | 2012-09-05 | 2016-12-06 | Amri Ssci, Llc | Cocrystals of progesterone |
| US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US10282282B2 (en) * | 2016-06-29 | 2019-05-07 | Synopsys, Inc. | Automated HTTP user flows simulator |
| EP3494106B1 (en) * | 2016-08-02 | 2022-07-20 | Journey Medical Corporation | Processes for making, and methods of using, glycopyrronium compounds |
| US20220298108A1 (en) * | 2019-05-23 | 2022-09-22 | Kaken Pharmaceutical Co., Ltd. | Crystalline form of sofpironium bromide and preparation method thereof |
-
2020
- 2020-05-22 US US17/611,158 patent/US20220298108A1/en active Pending
- 2020-05-22 KR KR1020217041385A patent/KR20220011671A/ko not_active Ceased
- 2020-05-22 CA CA3139948A patent/CA3139948A1/en active Pending
- 2020-05-22 BR BR112021023241A patent/BR112021023241A2/pt unknown
- 2020-05-22 EP EP20809754.3A patent/EP3972955A4/en active Pending
- 2020-05-22 SG SG11202111678WA patent/SG11202111678WA/en unknown
- 2020-05-22 MY MYPI2021006212A patent/MY206154A/en unknown
- 2020-05-22 TW TW109117164A patent/TWI838531B/zh active
- 2020-05-22 MX MX2021014163A patent/MX2021014163A/es unknown
- 2020-05-22 AU AU2020277881A patent/AU2020277881B2/en active Active
- 2020-05-22 CN CN202080034880.8A patent/CN114008023B/zh active Active
- 2020-05-22 TW TW112144978A patent/TWI870116B/zh active
- 2020-05-22 WO PCT/JP2020/020210 patent/WO2020235665A1/en not_active Ceased
- 2020-05-22 IL IL288285A patent/IL288285B1/en unknown
- 2020-05-22 JP JP2020089283A patent/JP6748329B1/ja active Active
- 2020-08-06 JP JP2020133620A patent/JP7605598B2/ja active Active
- 2020-11-25 US US17/105,376 patent/US11566000B2/en active Active
- 2020-11-26 PH PH1/2021/552915A patent/PH12021552915A1/en unknown
-
2021
- 2021-06-30 US US17/364,445 patent/US11584715B2/en active Active
- 2021-11-18 CL CL2021003047A patent/CL2021003047A1/es unknown
- 2021-11-24 ZA ZA2021/09514A patent/ZA202109514B/en unknown
- 2021-12-20 CO CONC2021/0017456A patent/CO2021017456A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020189856A (ja) | 2020-11-26 |
| IL288285B1 (en) | 2026-02-01 |
| TW202110796A (zh) | 2021-03-16 |
| SG11202111678WA (en) | 2021-11-29 |
| US20210395197A1 (en) | 2021-12-23 |
| JP2020189839A (ja) | 2020-11-26 |
| AU2020277881A1 (en) | 2021-12-09 |
| CN114008023A (zh) | 2022-02-01 |
| ZA202109514B (en) | 2023-12-20 |
| US11566000B2 (en) | 2023-01-31 |
| CL2021003047A1 (es) | 2022-09-20 |
| AU2020277881B2 (en) | 2025-03-06 |
| CO2021017456A2 (es) | 2022-01-17 |
| US11584715B2 (en) | 2023-02-21 |
| EP3972955A4 (en) | 2023-07-05 |
| TW202411205A (zh) | 2024-03-16 |
| KR20220011671A (ko) | 2022-01-28 |
| CN114008023B (zh) | 2024-02-09 |
| IL288285A (en) | 2022-01-01 |
| BR112021023241A2 (pt) | 2022-01-04 |
| TWI870116B (zh) | 2025-01-11 |
| MX2021014163A (es) | 2022-01-04 |
| JP6748329B1 (ja) | 2020-08-26 |
| TWI838531B (zh) | 2024-04-11 |
| EP3972955A1 (en) | 2022-03-30 |
| JP7605598B2 (ja) | 2024-12-24 |
| US20220298108A1 (en) | 2022-09-22 |
| PH12021552915A1 (en) | 2022-04-04 |
| MY206154A (en) | 2024-12-02 |
| WO2020235665A1 (en) | 2020-11-26 |
| US20210171460A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2771314C1 (ru) | Производные хинолинпирролидин-2-она и их применение | |
| CA2688694C (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| EP2280955B1 (en) | Crystalline form of 6-ý(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl¨pyridazin-3-amine | |
| US11584715B2 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| EP3604302A1 (en) | Preparation of crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate | |
| RU2012131344A (ru) | Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения | |
| UA112847C2 (uk) | ОКСАЛАТНА СІЛЬ КОН'ЮГАТА mPEG7-O-НАЛОКСОЛУ (ВАРІАНТИ), СПОСІБ ЇЇ ОТРИМАННЯ (ВАРІАНТИ) ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ | |
| CA3005450A1 (en) | Fumagillol derivatives and polymorphs thereof | |
| CA2510280C (en) | Process for the preparation of the r,r (or s,s) configured glycopyrronium stereoisomer | |
| WO2011091513A1 (en) | Polymorphic forms of lubiprostone | |
| JP7624089B2 (ja) | フッ素置換ピリドピラゾール系化合物の結晶形及びその製造方法 | |
| KR20250111319A (ko) | 다환 구조를 포함하는 감마-아미노뷰티르산 유도체, 이의 제조 방법 및 이의 용도 | |
| HK40068368A (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| HK40068368B (zh) | 索吡溴铵的晶型及其制备方法 | |
| WO2023194547A1 (en) | Birinapant polymorph h | |
| TW202537962A (zh) | 抑制α-V β-1整合素 | |
| HK40041289A (en) | Quinolino-pyrrolidin-2-one derivative and application thereof | |
| HK40041289B (en) | Quinolino-pyrrolidin-2-one derivative and application thereof | |
| HK40076742B (zh) | 新型三苯基化合物盐 | |
| JP2011522016A (ja) | ４−ブロモフェニル１，４−ジアザビシクロ［３．２．２］ノナン−４−カルボキシラートのフマル酸塩、この結晶形態、調製、および治療的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220824 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241004 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250512 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250512 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250710 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250710 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251218 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260116 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260413 |